2,955
+0.17%
Close of 9 Nov 2026, in KRW
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About PharmGen Science
Its shares trade on KRX under the ticker 004720.KS. It has been listed since 15 June 1990. In the fiscal year to 31 December 2025, it reported revenue of ₩173.07bn and a net loss of ₩116.64bn. At that date it held total assets of ₩195.41bn and shareholders' equity of ₩146.30bn.
PharmGen Science, Inc. engages in the development and production of medicaments. The company is headquartered in Hwaseong, Gyeonggi-Do. The Company’s products include antiepileptic agents, anti-inflammatory agents, antiphlogistic agents, central nervous system agents, urinary agents, antihistamine agents, antivirus agents, agents for bones, agents for livers, calcium agents, antibiotics, diabetes agents, respiratory agents, as well as over-the-counter (OTC) drugs, obesity drugs, health food and others. In addition, the Company is also engaged in the manufacturing, wholesale and retail distribution of functional cosmetics. The firm distributes its products within domestic market and to overseas markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 15 Jun 1990
- Website
- wooridulpharm.com ↗
Leadership
Pay as last reported
- Mr. Ui Sang HanChairman, since 2011₩602.5m
- Ms. Hye Yeon KimCo-Chief Executive Officer, Director
- Mr. Hui Deok ParkCo-Chief Executive Officer, Director
- Mr. Geun Hyeong LeeVice Chairman, since 2011
- Mr. Nam Hyeon RyuVice Chairman, since 2011
- Mr. Bok Hyeon NamInternal Auditor
- Mr. Seong Mun ParkInternal Auditor
- Mr. Yeong Ho ChoiDirector
- Mr. Chung Wu KimNon-Executive Independent Director
- Mr. Oh Yeong KimNon-Executive Independent Director
- Mr. Gi Mok HanIR Contact Officer
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- PharmGen Science Inc develops antiepileptic agents and antihistamine agents in KR.
- The company produces antiphlogistic agents and central nervous system agents for domestic markets.
- PharmGen Science Inc manufactures OTC drugs and obesity drugs in Hwaseong, Gyeonggi-Do.
Weaknesses
- PharmGen Science Inc focuses on domestic market distribution only.
- The company lacks international expansion in overseas markets.
- PharmGen Science Inc does not produce diabetes agents for export.
Opportunities
- PharmGen Science Inc can expand OTC drug distribution to overseas markets.
- The company can increase production of functional cosmetics for global markets.
- PharmGen Science Inc may develop new antiviral agents for international demand.
Threats
- PharmGen Science Inc faces competition from domestic pharmaceutical firms in KR.
- The company must comply with strict health regulations in KR.
- PharmGen Science Inc risks supply chain disruptions in Hwaseong.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.